Purpose Tyrosine kinase inhibitors (TKI) of the epidermal growth factor receptor (EGFR) are
becoming the standard treatments for Chinese patients with advanced non-small cell lung …

Herein, we present a randomized phase III Italian-Canadian trial named TORCH (Tarceva or
Chemotherapy). In TORCH, we are investigating whether erlotinib as first-line therapy until …

Evidence has suggested survival benefits of maintenance for advanced NSCLC patients not
progressing after first‐line chemotherapy. Additionally, particular first‐line targeted therapies …

Introduction Gefitinib, erlotinib, and afatinib represent the approved first‐line options for
epidermal growth factor receptor (EGFR)‐mutant non‐small cell lung cancer (NSCLC) …

In patients with advanced non-small cell lung cancer (NSCLC), the benefit-to-risk ratio of
doublet-targeted agents versus single agent is not clear. A systematic review and …

8074 Background: Erlotinib is an EGFR tyrosine kinase inhibitor (TKI) which is FDA-
approved at the maximum tolerated dose (MTD) of 150mg daily with dose limiting toxicities …

Erlotinib is a potent reversible HER1/epidermal growth factor receptor tyrosine kinase
inhibitor with single-agent activity in patients with non-small cell lung cancer. The aim of this …

Background The tyrosine kinase inhibitor erlotinib improves the outcomes of patients with
advanced non-small-cell lung carcinoma (NSCLC) harbouring epidermal growth factor …

Introduction Epidermal growth factor receptor tyrosine kinase inhibitors (TKIs) administered
concurrently with chemotherapy did not improve outcome. However, in preclinical models …

7022 Background: In phase II studies, erlotinib has shown single agent activity in a number
of tumor types, including NSCLC. NCIC CTG BR. 21 is a randomized, placebo-controlled …